Risk Management
| << Back | Download |
Risk Management Update: Biosimilars to Treat ROP
June 25, 2024
Dear Colleague:
We would like to provide you with an update on the use of biosimilars to treat ROP.
FDA-approved biosimilars are now available for bevacizumab, ranibizumab, and aflibercept for a variety of diseases. However, data on their use in ROP are very limited or absent with respect to plasma levels of drug at multiple time points, alteration of disease course, visual outcomes, and neurodevelopmental status.
Until such data become available, biosimilar drugs should NOT be used to treat ROP.
Download OMIC’s revised consent for treating ROP with injection which reflects this update on the use of biosimilars.
Contact your underwriter for any questions about coverage. Find my underwriter on OMIC’s webpage can give you the name, email address, and phone number of the underwriting contact for your state.
Remember that you may contact the Risk Management Hotline for confidential assistance by emailing us at riskmanagement@omic.com or calling 800-562-6642, option 4.
Sincerely,
R. Michael Siatkowski, MD
Chair of the OMIC ROP Task Force
_________________________________
